On 17 June 2024, Merck (known as MSD outside the US and Canada) announced that the US FDA has approved its anti-PD-1 therapy, Keytruda® (pembrolizumab) in combination with carboplatin and paclitaxel for primary advanced or recurrent endometrial carcinoma.
This is the first FDA-approved anti-PD-1 therapy for this indication and the third FDA-approved indication for Keytruda® in endometrial carcinoma. Keytruda received FDA-approval in March 2022 as a single agent for advanced endometrial carcinoma that is MSI-H or dMMR, and in combination with lenvatinib for such cancer that is not MSI-H or dMMR.